Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q1 2021 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2020 Net Income-$654.77K-$654.77KN/M vs Q1 2020 EPS Diluted-$0.01-$0.01N/M vs Q1 2020 Operating Income-$659,732N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
ended Nov 30, 2020 · filed Jan 14, 2021 · 45 d after period end